Is insulin the most effective injectable antihyperglycaemic therapy?
Buse JB, Peters A, Russell-Jones D, et al. Diabetes Obes Metab. 2015;17(2):145-151.
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell JE, Drucker DJ. Cell Metab. 2013;17:819-837.
Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk.
Chow E, Bernjak A, Williams S, et al. Diabetes. 2014;63(5):1738-1747.
Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
Diamant M, Nauck MA, Shaginian R, et al. Diabetes Care. 2014;37(10):2763-2773.
Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis.
Eng C, Kramer CK, Zinman B, Retnakaran R. Lancet. 2014;384(9961):2228-2234.
Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus.
Harris KB, McCarty DJ. Ther Adv Endocrinol Metab. 2015;6(1):3-18.
Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.
Sun F, Chai S, Li L, et al. J Diabetes Res. 2015;2015:157201.
Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies.
Wang T, Wang F, Gou Z, et al. Diabetes Obes Metab. 2015;17(1):32-41.
Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.
Wysham CH, MacConell LA, Maggs DG, et al. Mayo Clin Proc. 2015;90(3):356-365.
Guidelines
Standards of medical care in diabetes—2015.
American Diabetes Association. Diabetes Care. 2015;38(suppl1):S1-S94.
AACE/ACE comprehensive diabetes management algorithm 2015.
Garber AJ, Abrahamson MJ, Barzilay JI, et al. Endocr Pract.2015;21(4):438-447.
AACE/ACE clinical practice guidelines for developing a diabetes mellitus comprehensive care plan—2015.
Handelsman Y, Bloomgarden ZT, Grunberger G, et al. Endocr Pract. 2015;21(suppl 1):1-87